Ponatinib, a multi-targeted receptor tyrosine kinase inhibitor, has previously demonstrated efficacy in binding to PD-L1 and inhibiting melanoma growth, so one study assessed its ability to induce antitumor immunity in a murine GBM model [42]. The gene discussed is CD274; the disease is glioblastoma.